These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30810067)

  • 1. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
    Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
    Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling.
    Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D
    Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
    Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF).
    Epstein Shochet G; Brook E; Israeli-Shani L; Edelstein E; Shitrit D
    Respir Res; 2017 Jun; 18(1):122. PubMed ID: 28629363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.
    Joannes A; Brayer S; Besnard V; Marchal-Sommé J; Jaillet M; Mordant P; Mal H; Borie R; Crestani B; Mailleux AA
    Am J Physiol Lung Cell Mol Physiol; 2016 Apr; 310(7):L615-29. PubMed ID: 26773067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
    Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.
    MacKenzie B; Korfei M; Henneke I; Sibinska Z; Tian X; Hezel S; Dilai S; Wasnick R; Schneider B; Wilhelm J; El Agha E; Klepetko W; Seeger W; Schermuly R; Günther A; Bellusci S
    Respir Res; 2015 Jul; 16(1):83. PubMed ID: 26138239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
    Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
    Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.
    Bourne MH; Kottom TJ; Hebrink DM; Choudhury M; Leof EB; Limper AH
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition.
    Conte E; Gili E; Fruciano M; Korfei M; Fagone E; Iemmolo M; Lo Furno D; Giuffrida R; Crimi N; Guenther A; Vancheri C
    Lab Invest; 2013 May; 93(5):566-76. PubMed ID: 23439433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.
    Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E
    Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
    Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
    Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.